Capecitabine Accord
capecitabine
Keep this leaflet. You may need to read it again.
If you have any further questions, ask your doctor or pharmacist.
This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet (see section 4).
What Capecitabine Accord is and what it is used for
What you need to know before you take Capecitabine Accord
How to take Capecitabine Accord
Possible side effects
How to store Capecitabine Accord
Contents of the pack and other information
Capecitabine Accord belongs to the group of medicines called "cytostatic medicines", which stop the growth of cancer cells. Capecitabine Accord contains capecitabine, which itself is not a cytostatic medicine. Only after being absorbed by the body is it changed into an active anti-cancer medicine (more in tumour tissue than in normal tissue).
Capecitabine Accord is used in the treatment of colon, rectal, gastric, or breast cancers. Furthermore, Capecitabine Accord is used to prevent new occurrence of colon cancer after complete removal of the tumour by surgery.
Capecitabine Accord may be used either alone or in combination with other medicines.
if you are allergic to capecitabine or any of the other ingredients of this medicine (listed in section 6). You must inform your doctor if you know that you have an allergy or over-reaction to this medicine,
if you previously have had severe reactions to fluoropyrimidine therapy (a group of anticancer medicines such as fluorouracil),
if you are pregnant or breast-feeding,
if you have severely low levels of white cells or platelets in the blood (leucopenia, neutropenia or thrombocytopenia)
if you have severe liver or kidney problems,
if you know that you do not have any activity of the enzyme dihydropyrimidine dehydrogenase (DPD) (complete DPD deficiency).
if you are being treated now or have been treated in the last 4 weeks with brivudine as part of herpes zoster (chickenpox or shingles) therapy.
Talk to your doctor or pharmacist before taking Capecitabine Accord, if you
know that you have a partial deficiency in the activity of the enzyme dihydropyrimidine dehydrogenase (DPD)
have a family member who has partial or complete deficiency of the enzyme dihydropyrimidine dehydrogenase (DPD)
have liver or kidney diseases
have or had heart problems (for example an irregular heart beat) or pains to the chest, jaw and back, brought on by physical effort and due to problems with the blood flow to the heart
have brain diseases (for example cancer that has spread to the brain) or nerve damage (neuropathy)
have calcium imbalances (seen in blood tests)
have diabetes
cannot keep your food or water in your body because of severe nausea and vomiting
have diarrhoea
are or become dehydrated
have imbalances of ions in your blood (electrolyte imbalances, seen in test)
have a history of eye problems as you may need extra monitoring of your eyes
have severe skin reaction
DPD deficiency:
DPD deficiency is a genetic condition that is not usually associated with health problems unless you receive certain medicines. If you have DPD deficiency and take Capecitabine Accord, you are at an
increased risk of severe side effects (listed under section 4 Possible side effects). It is recommended to
test you for DPD deficiency before start of treatment. If you have no activity of the enzyme you should not take Capecitabine Accord. If you have a reduced enzyme activity (partial deficiency) your doctor might prescribe a reduced dose. If you have negative test results for DPD deficiency, severe and life-threatening side effects may still occur.
Capecitabine Accord is not indicated in children and adolescent. Do not give Capecitabine Accord to children and adolescent.
Before starting treatment, tell your doctor or pharmacist if you are taking, have recently taken or might
take any other medicines. This is extremely important, as taking more than one medicine at the same time can strengthen or weaken the effect of the medicines.
Also you need to be particularly careful if you are taking any of the following:
gout medicines (allopurinol),
blood-thinning medicines (coumarin, warfarin),
medicines for seizures or tremors (phenytoin)
a medicine to treat cancer (interferon alpha)
radiotherapy and certain medicines used to treat cancer (folinic acid, oxaliplatin, bevacizumab, cisplatin, irinotecan)
Medicines used to treat folic acid deficiency.
You should take Capecitabine Accord no later than 30 minutes after meals.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
You must not take Capecitabine Accord if you are pregnant or think you might be.
You must not breast-feed if you are taking Capecitabine Accord and for 2 weeks after the last dose. If you are a woman who could become pregnant you should use effective contraception during treatment with Capecitabine Accord and for 6 months after the last dose.
If you are a male patient and your female partner could become pregnant, you should use effective contraception during treatment with Capecitabine Accord and for 3 months after the last dose.
Capecitabine Accord may make you feel dizzy, nauseous or tired. It is therefore possible that
Capecitabine Accord could affect your ability to drive a car or operate machines. Do not drive if you feel dizzy, nauseous or tired after taking this medicine.
This medicine contains lactose. If you have been told by your doctor that you have an intolerance to
some sugars, contact your doctor before taking this medicine.
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
Capecitabine Accord should only be prescribed by a doctor experienced in the use of anticancer medicines.
Your doctor will prescribe a dose and treatment regimen that is right for you. The dose of Capecitabine Accord is based on your body surface area. This is calculated from your height and weight. The usual dose for adults is 1250 mg/m2 of body surface area taken two times daily (morning and evening). Two examples are provided here: A person whose body weight is 64 kg and height is
1.64 m has a body surface area of 1.7 m2 and should take 4 tablets of 500 mg and 1 tablet of 150 mg two times daily. A person whose body weight is 80 kg and height is 1.80 m has a body surface area of
2.00 m2 and should take 5 tablets of 500 mg two times daily.
Your doctor may want you to take a combination of 150 mg and 500 mg tablets for each dose.
Take the tablets morning and evening as prescribed by your doctor.
Take the tablets within 30 minutes after the end of a meal (breakfast and dinner) and swallow them whole with water. Do not crush or cut tablets. If you cannot swallow
It is important that you take all your medicine as prescribed by your doctor.
Capecitabine Accord tablets are usually taken for 14 days followed by a 7 day rest period (when no tablets are taken). This 21 day period is one treatment cycle.
In combination with other medicines the usual dose for adults may be less than 1250 mg/m2 of body surface area, and you may need to take the tablets over a different time period (e.g. every day, with no rest period).
If you take more Capecitabine Accord than you should, contact your doctor as soon as possible before taking the next dose.
You might get the following side effects if you take a lot more capecitabine than you should, feeling or
being sick, diarrhoea, inflammation or ulceration of the gut or mouth, pain or bleeding from the intestine or stomach, or bone marrow depression (reduction in certain kinds of blood cells). Tell your doctor immediately if you experience any of these symptoms.
Do not take the missed dose at all. Do not take a double dose to make up for a forgotten dose.Instead, continue your regular dosing schedule and check with your doctor.
There are no side-effects caused by stopping treatment with capecitabine. In case you are using coumarin anticoagulants (containing e.g. phenprocoumon), stopping capecitabine might require that your doctor adjusts your anticoagulant dose.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Diarrhoea: if you have an increase of 4 or more bowel movements compared to your normal bowel movements each day or any diarrhoea at night.
Vomiting: if you vomit more than once in a 24-hour time period.
Nausea: if you lose your appetite, and the amount of food you eat each day is much less than usual.
Stomatitis: if you have pain, redness, swelling or sores in your mouth and/or throat.
Hand-and-foot skin-reaction: if you have pain, swelling, redness or tingling of hands and/or feet
Fever: if you have a temperature of 38°C or greater.
Infection: if you experience signs of infection caused by bacteria or virus, or other organisms.
Chest pain: if you experience pain localised to the centre of the chest, especially if it occurs during exercise.
Steven-Johnson syndrome: if you experience painful red or purplish rash that spreads and blisters and/or other lesions begin to appear in the mucous membrane (e.g. mouth and lips), in particular if you had before light sensitivity, infections of the respiratory system (e.g. bronchitis) and/or fever.
DPD Deficiency: if you have a known DPD deficiency, you are at an increased risk of acute early-onset of toxicity and severe, life-threatening, or fatal adverse reactions caused by Capecitabine Accord (e.g. stomatitis, mucosal inflammation, diarrhoea, neutropenia, and neurotoxicity).
throat which makes it difficult to swallow or breathe, itching and rashes. This could be a sign of angioedema.
If caught early, these side effects usually improve within 2 to 3 days after treatment discontinuation. If
these side effects continue, contact your doctor immediately. Your doctor may instruct you to restart treatment at a lower dose.
If severe stomatitis (sores in your mouth and/or throat), mucosal inflammation, diarrhoea, neutropenia (increased risk for infections), or neurotoxicity occurs during the first cycle of treatment a DPD deficiency may be involved (please see Section 2: Warning and precautions).
Hand and foot skin-reaction can lead to loss of fingerprint, which could impact your identification by fingerprint scan.
In addition to the above, when capecitabine is used alone, the very common side effects which may affect more than 1 in 10 people are:
abdominal pain
rash, dry or itchy skin
tiredness
loss of appetite (anorexia)
These side effects can become severe; therefore, it is important that you always contact your doctor immediately when you start to experience a side effect. Your doctor may instruct you to decrease the dose and/or temporarily discontinue treatment with Capecitabine Accord. This will help reduce the likelihood that the side effect continues or becomes severe
Other side effects are:
Common side effects (may affect up to 1 in 10 people) include:
decreases in the number of white blood cells or red blood cells (seen in tests)
dehydration, weight loss
sleeplessness (insomnia), depression
headache, sleepiness, dizziness, abnormal sensation in the skin (numbness or tingling sensation), taste changes
eye irritation, increased tears, eye redness (conjunctivitis)
inflammation of the veins (thrombophlebitis)
shortness of breath, nose bleeds, cough, runny nose
cold sores or other herpes infections
infections of the lungs or respiratory system (e.g. pneumonia or bronchitis)
bleeding from the gut, constipation, pain in upper abdomen, indigestion, excess wind, dry mouth
skin rash, hair loss (alopecia), skin reddening, dry skin, itching (pruritus), skin discolouration, skin loss, skin inflammation, nail disorder
pain in the joints or in the limbs (extremities), chest or back
fever, swelling in the limbs, feeling ill
problems with liver function (seen in blood tests) and increased blood bilirubin (excreted by the liver)
Uncommon side effects (may affect up to 1 in 100 people) include:
blood infection, urinary tract infection, infection of the skin, infections in the nose and throat, fungal infections (including those of the mouth), influenza, gastroenteritis, tooth abscess,
lumps under the skin (lipoma)
decreases in blood cells including platelets, thinning of blood (seen in tests)
allergy
diabetes, decrease in blood potassium, malnutrition, increased blood triglycerides
confusional state, panic attacks, depressed mood, decreased libido
difficulty speaking, impaired memory, loss of movement coordination, balance disorder, fainting, nerve damage (neuropathy) and problems with sensation
blurred or double vision
vertigo, ear pain
irregular heartbeat and palpitations (arrhythmias), chest pain and heart attack (infarction)
blood clots in the deep veins, high or low blood pressure, hot flushes, cold limbs (extremities), purple spots on the skin
blood clots in the veins in the lung (pulmonary embolism), collapsed lung, coughing up blood,
asthma, shortness of breath on exertion
bowel obstruction, collection of fluid in the abdomen, inflammation of the small or large intestine, the stomach or the oesophagus, pain in the lower abdomen, abdominal discomfort, heartburn (reflux of food from the stomach), blood in the stool
jaundice (yellowing of skin and eyes)
skin ulcer and blister, reaction of the skin with sunlight, reddening of palms, swelling or pain of the face
joint swelling or stiffness, bone pain, muscle weakness or stiffness
fluid collection in the kidneys, increased frequency of urination during the night, incontinence, blood in the urine, increase in blood creatinine (sign of kidney dysfunction)
unusual bleeding from the vagina swelling (oedema), chills and rigors
Some of these side effects are more common when capecitabine is used with other medicines for the treatment of cancer. Other side-effects seen in this setting are the following:
Common side effects (may affect up to 1 in 10 people) include:
decrease in blood sodium, magnesium or calcium, increase in blood sugar
nerve pain
ringing or buzzing in the ears (tinnitus), loss of hearing
vein inflammation
hiccups, change in voice
pain or altered/abnormal sensation in the mouth, pain in the jaw
sweating, night sweats
muscle spasm
difficulty in urination, blood or protein in the urine
bruising or reaction at the injection site (caused by medicines given by injection at the same time)
Rare side effects (may affect up to 1 in 1,000 people) include:
narrowing or blockage of tear duct (lacrimal duct stenosis)
liver failure
inflammation leading to dysfunction or obstruction in bile secretion (cholestatic hepatitis)
specific changes in the electrocardiogram (QT prolongation)
certain types of arrhythmias (including ventricular fibrillation, torsade de pointes, and bradycardia)
eye inflammation causing eye pain and possibly eyesight problems
inflammation of the skin causing red scaly patches due to an immune system illness
Angioedema (swelling mainly of the face, lip, tongue or throat, itching and rashes)
Very rare side effects (may affect up to 1 in 10,000 people) include:
severe skin reaction such as skin rash, ulceration and blistering which may involve ulcers of the mouth, nose, genitalia, hands, feet and eyes (red and swollen eyes).
If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting
system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. For Aluminium-aluminium blisters
This medicine does not require any special storage conditions.
For PVC/PVdC-aluminium blisters (perforated unit dose) Do not store above 30°C.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment
The active substance is capecitabine.
Each film-coated tablet contains 150 mg of capecitabine Each film-coated tablet contains 300 mg of capecitabine
Each film-coated tablet contains 500 mg of capecitabine
The other ingredients are:
Tablet core: anhydrous lactose, croscarmellose sodium, hypromellose,microcrystalline cellulose, magnesium stearate
Tablet coating (for 150 mg): Hypromellose, titanium dioxide (E171), yellow ironoxide,
red iron oxide (E172), talc
Tablet coating (for 300 mg): Hypromellose, titanium dioxide (E171), talc
Tablet coating (for 500 mg): Hypromellose, titanium dioxide (E171), yellow ironoxide, red iron oxide (E172), talc
Capecitabine Accord 150 mg film-coated tablets are light peach coloured, oblong shaped, biconvex, film-coated tablets of 11.4 mm in length and 5.3 mm in width, debossed with ‘150’ on one side and plain on other side.
Capecitabine Accord 300 mg film-coated tablets are white to off white, oblong shaped, biconvex, film-coated tablets of 14.6 mm in length and 6.7 mm in width, debossed with ‘300’ on one side and plain on other side.
Capecitabine Accord 500 mg film-coated tablets are peach coloured, oblong shaped, biconvex, film-coated tablets of 15.9 mm in length and 8.4 mm in width, debossed with ‘500’ on one side and plain on other side.
Capecitabine Accord is available in blister packs containing 30, 60 or 120 film-coated tablets or in perforated unit dose blister packs containing 30 x 1, 60 x 1 or 120 x 1 film-coated tablets.
Not all pack sizes may be marketed.
Accord Healthcare S.L.U.
World Trade Center, Moll de Barcelona, s/n, Edifici Est 6ª planta,
08039 Barcelona,
Spain
Accord Healthcare Polska Sp.z o.o.,
ul. Lutomierska 50,95-200 Pabianice, Poland
Accord Healthcare B.V., Winthontlaan 200,
3526 KV Utrecht, The Netherlands